Cite
Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial.
MLA
Butler, Javed, et al. “Patiromer for the Management of Hyperkalaemia in Patients Receiving Renin-Angiotensin-Aldosterone System Inhibitors for Heart Failure: Design and Rationale of the DIAMOND Trial.” European Journal of Heart Failure. Supplements, vol. 24, no. 1, Jan. 2022, pp. 230–38. EBSCOhost, https://doi.org/10.1002/ejhf.2386.
APA
Butler, J., Anker, S. D., Siddiqi, T. J., Coats, A. J. S., Dorigotti, F., Filippatos, G., Friede, T., Göhring, U.-M., Kosiborod, M. N., Lund, L. H., Metra, M., Quinn, C. M., Piña, I. L., Pinto, F. J., Rossignol, P., Szecsödy, P., Van Der Meer, P., Weir, M., & Pitt, B. (2022). Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. European Journal of Heart Failure. Supplements, 24(1), 230–238. https://doi.org/10.1002/ejhf.2386
Chicago
Butler, Javed, Stefan D. Anker, Tariq Jamal Siddiqi, Andrew J. S. Coats, Fabio Dorigotti, Gerasimos Filippatos, Tim Friede, et al. 2022. “Patiromer for the Management of Hyperkalaemia in Patients Receiving Renin-Angiotensin-Aldosterone System Inhibitors for Heart Failure: Design and Rationale of the DIAMOND Trial.” European Journal of Heart Failure. Supplements 24 (1): 230–38. doi:10.1002/ejhf.2386.